Micron Month Rally Triggers Sell Debate in May Amid AI Boom
Micron Technology rides a rapid AI-fueled rally into May, fueling debate among investors about whether to sell or hol...
Articles — Page 1429
Trump Walks Into Beijing as Oil Turmoil Looms Worldwide
Iran's Kharg Island oil terminal has halted loading for multiple days as President Trump arrives in Beijing. The disr...
Live: Rare Earth Reports Eyes Q1 Results Rally
USA Rare Earth is set to publish its Q1 2026 results after market close as investors await production updates and the...
Live: Doximity Earnings Tonight Could Spark a Rebound Wave
Doximity is due to report Q4 results after the close, with analysts keyed to FY2027 guidance and margin trajectory as...
America’s Data Centers Thirsty: Rural Towns Pay the Price
Rural communities from Georgia to Arizona report dipping water pressure as data centers expand. Regulators are steppi...
Senate Confirms Kevin Warsh as Fed Chair: Market Reaction
The Senate confirmed Kevin Warsh to lead the Federal Reserve, setting the stage for policy shifts as inflation stays ...
Ford’s Stock Leads S&P 500 as Biggest Gainer on Energy
Ford’s stock surged to top the S&P 500 after a bullish Morgan Stanley note highlighted the automaker’s growing energy...
Alex Murdaugh Convicted Killing: Wealth and Risk Lessons
A high-profile murder case can rewrite the map of your finances. This article uses the Alex Murdaugh case to show pra...
This Ford Plans Drive Momentum Into Summer with Strategy
Ford kicked off the year with strong truck demand and a raised outlook. Now the automaker aims to sustain momentum in...
Second Wave Will Mint More Millionaires and Stocks to Own
The AI landscape is shifting from a few hardware champions to a broad ecosystem of software, cloud, and microchips. L...
Reasons Into Hantavirus-Related Biotech: 3 Cautions
A hantavirus outbreak can spark biotech chatter, but three solid realities—limited demand, tough development paths, a...
Is Novo Nordisk's Rebound Real--Or Head Fake for Investors?
After a steep slide, Novo Nordisk has shown fresh momentum. But can the rebound sustain, or is it just a temporary bo...